Abstract:Background Beyond the known risk factors such as age over 50, unhealthy diet, ethnicity, and smoking, emerging evidence suggests that gut microbial dysbiosis plays a crucial role in the early stages of colorectal cancer (CRC) by contributing to chronic inflammation and various intestinal dysfunctions. Even though various bacterial species have been studied, the gut microbiome profile as a representative biomarker in CRC patients remains largely unreported. This study presents a comparative analysis of the microbiome profiles of fecal and mucosal samples from CRC patients, followed by metagenomic profiling investigation to validate dominant bacteria in each sample type of CRC patients. Methods The study involved 12 patients receiving CRC resection at Myongji Hospital in South Korea, recruited from May 2020 to June 2021. Fecal samples were collected pre-surgery, and mucosal samples during surgery. Paired-end sequencing was performed using Illumina MiSeq (Illumina, San Diego, USA) platform. 16s rRNA gene-based microbiome profiling was analyzed using QIIME2 (V.2020.11), a plugin-based platform for microbiome analysis. Sequencing reads were filtered, denoised, and clustered into amplicon sequence variants (ASVs) using DADA2 included in QIIME2. Taxonomic classification was assigned in the QIIME2 pipeline using a pre-trained classifier based on the Silva 138.1 reference sequence. Linear discriminant analysis (LDA) effect size (LEfSe) analysis was performed with LDA score ≥3.0 and p-value of 0.05. Results The study subjects included 12 Korean patients, with an average age of 71 ± 10 years. The gender distribution included 3 men and 9 women whose body mass index was 24.6 ± 2.4 (mean ± SD). There was significant difference observed in UniFrac beta-diversity between the two groups (p=0.001). The relative taxonomic patterns of the microbiota between CRC stool and tissue showed that Bacteroides and Fusobacterium were more dominant in tissue than stool at both phylum and genus levels. Further taxonomic differences between the samples revealed that Firmicutes, Bacilli, and Lactobacillacease were over-represented in CRC patient stool, while Pseudomonadales (p<0.001) and Pseudomonas (p<0.001) were identified in the mucosal tissue. Conclusion Our findings revealed that notable distinction was observed in the beta-diversity, indicating a unique microbial composition in tissue. Specifically, higher prevalence of Bacteroides and Fusobacterium at the genus level were identified in tissue. Additionally, our analysis highlighted Pseudomonadales and Pseudomonas emerged in CRC mucosal tissues. Furthermore, by comparing with a healthy control group, we aim to further elucidate potential markers unique to CRC patients. Citation Format: Sanghun Lee. Comparative Microbiome Analysis of Paired Mucosal and Fecal Samples in Korean Colorectal Cancer Patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 758.

Microbiota and colorectal cancer — controlling for confounders challenges associations

Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development

Abstract 3062: Modifiable factors and gut microbiome alteration among colorectal cancer patients

Dysbiotic microbiome variation in colorectal cancer patients is linked to lifestyles and metabolic diseases

Mucosa-associated microbiota signature in colorectal cancer

Deciphering the Colorectal Cancer Gut Microbiota: Association vs. Causality

Comparison of the Human Gut Microbiota between Normal Control Subjects and Patients with Colonic Polyps and Colorectal Cancer

Changes of intestinal microbiota in colorectal cancer and its potential ability to predict disease

Abstract 758: Comparative Microbiome Analysis of Paired Mucosal and Fecal Samples in Korean Colorectal Cancer Patients

Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer

Microbiome and colorectal carcinogenesis: Linked mechanisms and racial differences

The gut microbiota can orchestrate the signaling pathways in colorectal cancer

Features of combined gut bacteria and fungi from a Chinese cohort of colorectal cancer, colorectal adenoma, and post-operative patients

Abstract 2807: Distinctive microbiome signatures in colorectal cancer: A comparative metagenomic analysis

Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers

Gut Microbiota Signatures in Tumor, Para-Cancerous, Normal Mucosa, and Feces in Colorectal Cancer Patients

Disease-associated Gut Microbiome and Critical Metabolomic Alterations in Patients with Colorectal Cancer

New Insights into Mucosa-Associated Microbiota in Paired Tumor and Non-Tumor Adjacent Mucosal Tissues in Colorectal Cancer Patients

Effect of gut microbiota in the colorectal cancer and potential target therapy

Colorectal cancer-associated bacteria are broadly distributed in global microbiomes and drivers of precancerous change

The gut microbiota, bacterial metabolites and colorectal cancer